Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon (ANNX) has granted a stock option inducement award to a new non-executive employee under its 2022 Employment Inducement Award Plan. The grant was approved on April 11, 2025, complying with Nasdaq Listing Rule 5635(c)(4).
The employee received options to purchase 105,000 shares of Annexon common stock at an exercise price of $1.54 per share, matching the closing price on April 15, 2025. The option has a ten-year term and vests over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
Annexon (ANNX) ha concesso un premio di opzioni su azioni a un nuovo dipendente non esecutivo nell'ambito del suo Piano di Incentivi per l'Assunzione 2022. La concessione è stata approvata l'11 aprile 2025, in conformità con la Regola Nasdaq 5635(c)(4).
Il dipendente ha ricevuto opzioni per acquistare 105.000 azioni ordinarie di Annexon a un prezzo di esercizio di 1,54 $ per azione, corrispondente al prezzo di chiusura del 15 aprile 2025. L'opzione ha una durata di dieci anni e si consolida in 4 anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente in rate di 1/48, subordinatamente alla continuazione del rapporto di lavoro.
Annexon (ANNX) ha otorgado un premio de opciones sobre acciones a un nuevo empleado no ejecutivo bajo su Plan de Incentivos por Contratación 2022. La concesión fue aprobada el 11 de abril de 2025, cumpliendo con la Norma Nasdaq 5635(c)(4).
El empleado recibió opciones para comprar 105,000 acciones comunes de Annexon a un precio de ejercicio de $1.54 por acción, igualando el precio de cierre del 15 de abril de 2025. La opción tiene un plazo de diez años y se adquiere en un período de 4 años, con un 25% que se consolida después del primer año y el resto que se consolida mensualmente en 1/48, condicionado a la continuidad del empleo.
Annexon (ANNX)은 2022년 고용 유인 보상 계획에 따라 새로운 비임원 직원에게 스톡옵션 유인 보상을 부여했습니다. 이 부여는 2025년 4월 11일에 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
직원은 2025년 4월 15일 종가와 동일한 주당 $1.54의 행사 가격으로 Annexon 보통주 105,000주를 구매할 수 있는 옵션을 받았습니다. 이 옵션은 10년 기간이며, 4년에 걸쳐 권리가 취득되며, 첫 해 후 25%가 취득되고 나머지는 매월 1/48씩 취득되며, 계속 고용 조건이 충족되어야 합니다.
Annexon (ANNX) a accordé une attribution d'options d'achat d'actions à un nouvel employé non cadre dans le cadre de son Plan d'Attribution d'Incitation à l'Emploi 2022. L'attribution a été approuvée le 11 avril 2025, conformément à la règle Nasdaq 5635(c)(4).
L'employé a reçu des options pour acheter 105 000 actions ordinaires d'Annexon à un prix d'exercice de 1,54 $ par action, correspondant au cours de clôture du 15 avril 2025. L'option a une durée de dix ans et se libère sur 4 ans, avec 25 % qui se débloquent après la première année et le reste qui se débloque mensuellement par tranches de 1/48, sous réserve de la poursuite de l'emploi.
Annexon (ANNX) hat einem neuen nicht geschäftsführenden Mitarbeiter im Rahmen seines Beschäftigungsanreizplans 2022 eine Aktienoptionszuteilung gewährt. Die Zuteilung wurde am 11. April 2025 genehmigt und entspricht der Nasdaq-Listing-Regel 5635(c)(4).
Der Mitarbeiter erhielt Optionen zum Kauf von 105.000 Aktien der Annexon-Stammaktien zu einem Ausübungspreis von 1,54 $ pro Aktie, entsprechend dem Schlusskurs am 15. April 2025. Die Option hat eine Laufzeit von zehn Jahren und wird über 4 Jahre erworben, wobei 25 % nach dem ersten Jahr und der Rest monatlich zu je 1/48 erworben werden, vorausgesetzt, das Arbeitsverhältnis besteht weiterhin.
- Company maintains ability to attract talent through equity compensation
- Stock price at $1.54 indicates significant decline from IPO levels
- Potential dilution for existing shareholders from 105,000 new shares
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on April 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 105,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What are the terms of ANNX's latest employee stock option grant in April 2025?
How does the vesting schedule work for ANNX's April 2025 inducement grant?
What was ANNX's stock price when the inducement grant was issued?
What is the purpose of ANNX's 2022 Employment Inducement Award Plan?
